Menu

Lasker Winners Announced

Discoveries related to rapid neurotransmitter release are among those recognized by the Albert and Mary Lasker Foundation this year.

Sep 9, 2013
Tracy Vence

Richard Scheller (left) of Genentech and Thomas Südhof (right) from Stanford University took home the 2013 Albert Lasker Basic Medical Research Award for their work on rapid neurotransmitter release.ALBERT AND MARY LASKER FOUNDATION

Genentech’s Richard Scheller and Thomas Südhof from the Stanford University School of Medicine have won the 2013 Lasker Award for basic medical research. Scheller, executive vice president of research and early development at the South San Francisco-based biotech, and Südhof are being lauded by the Albert and Mary Lasker Foundation for their work unraveling the molecular machinery and regulatory mechanisms behind rapid neurotransmitter release.

In its announcement, the foundation noted that Scheller and Südhof independently identified, isolated, and defined fundamental interactions among the key molecules involved in rapid neurotransmitter release “at a time . . . when not a single protein in the process had been characterized.”

Meantime, the foundation presented its 2013 Lasker Award for clinical research to three scientists who worked to develop the modern cochlear implant, and honored Bill and Melinda Gates for their public service work, “leading a historic transformation in the way we view the globe’s most pressing health concerns and improving the lives of millions of the world's most vulnerable.”

This year’s recipients will each receive a $250,000 honorarium, and will be presented with their awards on Friday, September 20, in New York City. 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.